San Diego-based DTx Pharma, a biotechnology company that uses RNA-based therapies to treat genetic factors of genetic diseases, raised $100 Million in a Series B round. 

Their platform, FALCON (Fatty Acid Ligand Conjugated Oligonucleotide), allows the team to look into diseases in skeletal muscle, cardiac muscle, and the peripheral nervous system. 

Read more about the funding here.